Once-weekly cagrilintide–semaglutide combination therapy produced unprecedented weight reductions in adults with overweight or obesity, with 60% achieving ≥20% loss and strong cardiometabolic benefits ...

Semaglutide was associated with improved maximum walking distance across type 2 diabetes subgroups among patients with ...

“I think the results are very encouraging, and I hope that industry will take it on and do a regulatory approval trial for semaglutide in type 1,” he added. The 26-week ADJUST-T1D randomized clinical ...

A clinical trial led by an Indiana University School of Medicine researcher found that weekly doses of semaglutide - a ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Combination therapy with a long-acting amylin analogue and a glucagon-like peptide-1 (GLP-1) receptor agonist results in ...

CagriSema vs placebo was associated with significant weight loss among adults with overweight or obesity with or without type ...

Researchers have found in phase IIIa REDEFINE 1 trial that Addition of investigational cagrilintide to GLP-1 agonist ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Another major insurance change coming next year will affect another large swath of Dushay’s patients: In January, BCBS ...

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...